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INTRODUCTION
Parkinson's disease (PD) is a neurodegenerative disorder
of the central nervous system (CNS) that occurs most
commonly in elderly people - about 1% of the population
over the age of 65 is affected.1 Symptoms result from a
single transmitter deficit due to the loss of dopamine in
the substantia nigra, pars compacta. The etiology is
unknown, but epidemiological studies have suggested that
exposure to toxins and v iruses may confer a
predisposition, along with life events and the aging
process. It is likely that about 70-80% of nigrostriatal
neurons have to cease functioning or die before symptoms
a p p e a r .2 Although nigral dopamine depletion is the
dominant deficit, other monoamine transmitters, such as
the noradrenergic locus coeruleus neurons,3,4,5 as well as
other cent ral  and periphera l systems such as
serotoninergic, cholinergic and peptidergic pathways are
also affected.6,7
Although genet ics l ike ly plays a role in  PD, most
researchers believe environmental exposures increase a
person's risk of developing the disease. There are a
number of toxins, such as 1-methy1-4-phenyl-1,2,3,6-
tetrahydropyridine, or MPTP (found in certain forms of
synthetic heroin), that can cause Parkinsonian symptoms
in humans. Other, still-unidentified environmental factors
also may cause PD in genetically susceptible individuals.
Several lines of research suggest that mitochondria may
play a role in the development of PD. Mitochondria are the
energy-producing components of the cell and are major
sources of  f ree radica ls molecules that damage
membranes, proteins, DNA, and other parts of the cell.7,8
The importance of decreased efficiency of mitochondrial
oxidative phosphorylation activity is multi-factorial.
Perhaps the most important consequence of inefficient
energy product ion is  a change in the neuronal
transmembrane potential. Several factors such as
inhibition of mitochondrial respiration, generation of
hydroxyl and nitric oxide radicals and reduced free radical
defense mechanisms causing oxidative stress have been
postulated to cont ribute to the degeneration of
dopaminergic neurons.8-10
On the other hand, the discovery of several genetic
mutations associated with PD raises the possibility that
these or other biomarkers may help to identify persons at
risk of PD.1 0 Some researchers even speculate that the
protein buildup is part of an unsuccessful attempt to
protect the cell. While mitochondrial dysfunction, oxidative
stress, inflammation, and many other cellular processes
may contribute to PD, the actual cause of dopamine cell
death remains undetermined.11
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ABSTRACT
Parkinson's disease is a neurological disorder of older individuals frequently encountered in clinical practice. Disparate
etiologic factors including infectious agents, genetic predisposition, environmental and toxic factors, metabolic
abnormalities, traumatic events, electromagnetic radiation exposure, antioxidants, sex hormones, pharmaceutical drugs and
others have been proposed. In this study, cerebrospinal fluid obtained by lumbar puncture is used to assess levels of
neurotransmitters in Parkinson's disease patients treated with L-dopa during On and Off periods. We found a correlation
between small peptides such as neuropeptide Y, substance P and cholecystokinin (both octa- and tetra- peptides) with the
classical neurotransmitters such as norephinepherine, dopamine and serotonin.
Pak J Neurol Sci 2007; 2(2):85-91
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The most effective therapy is L-dopa (levodopa), which is
most successful during the first years of PD. However,
after 5-10 years of L-dopa replacement, 80% of PD
patients show on and off phenomena with dyskinesias.11
This is most notable in advanced stages, where the
medication is unable to improve motor and non-motor
parkinsonian features and does not halt PD progression.
Levodopa can cross the blood-brain barrier and reduces
morbidity and mortality in PD. Despite disadvantages, it
remains the gold standard for the treatment of PD, mainly
on account of impressive efficacy on motor symptoms and
inexpensive price. Several motor features typically do not
respond to levodopa. Speech, gait, posture and balance
tend to deteriorate over the time. Side affects include
hallucinations, cognitive impairment and orthostatic
hypotension.
Neuropeptides, among other neurotransmitters, are widely
distributed throughout the brain in specific nerve cells,
coexist ing wi th monoamines and/or  other
n e u r o p e p t i d e s .1 2 , 1 3 They are believed to participate in
several physiological and patho-physiological processes,
including pain sensation, memory, neuroendocrine
functions, regulation of release of monoamine transmitters
and regulation of mood.14 The effects are brought about
by primary actions of neuropeptides or their modulation of
the effects of monoamine transmitters. Several peptides
such as neuropeptide Y (NPY), cholecystokinin (CCK),
substance P (SP), somatostatin and vasopressin are
known to co-localize with classical neurotransmitters
within a single neuron, which provides a means to
transmit more complex types of signals.15 On the basis of
co-existence with monoamine transmitters and distinct
regional distribution, the assumption has been made that
neuropeptides play a role in CNS disorders.16
This study deals with CSF analysis of small peptides such
as substance P, neuropeptide Y, both the tetra- and octa-
peptides of cholecystokinin, and the correlation between
catecholamines and smal l pept ides, as well  as
catechoamines and their metabolites in both on and off
PD pat ients.  These levels are reported with the
assumption that CSF concentration reflects brain or spinal
cord concentrations and perhaps synaptic activity, since
CSF is in constant exchange with the extra-cellular fluid of
the CNS. Based on the fact that most of the transmitters
in the brain are present in the CSF and that alterations in
the concentration of transmitters in the CSF can alter the
same transmitters in the brain,17 the results are compiled
in PD patients (On and Off groups) and compared with
healthy subjects.
METHODS
A total of 36 patients (15 women and 21 men) with PD
were recruited from the Department of Neurology,
Huddinge University Hospital, Stockholm, Sweden. The
Ethics Committee of the Karolinska Institute, Stockholm,
approved the study and all patients gave written informed
consent to participate. 
Patients were divided into two groups. The first group
included 18 patients, each at different stages of illness
(Hoehn and Yar range 2-4), who were on L-dopa dose
250 mg per day and had taken it in combination with
other drugs with positive response towards their motor
activities (PD On group). Another 18 PD patients who had
been treated for 6-8 years with similar drug therapy, and
showed motor fluctuations with severe off response (PD
Off group) were also included. Both On and Off groups
were monitored one week before samples of blood and
CSF were taken. Food and fluid intake were similar in both
groups and exact dose timings were maintained. Blood
and CSF were taken early in the morning, between 6-8
AM, in a fasting condition. A control group of 18 healthy
volunteers (recruited from among the Karolinska Institute
employees) were used for comparison, and had their
blood and CSF samples collected under conditions similar
to the patient groups. None of the healthy controls had
been on any medication for the past six months. For both
PD cases and healthy controls,10-12 ml CSF was
collected in the sitting position at the L4-L5 levels. Blood
samples were collected by venipuncture. Serum and CSF
albumin and IgG levels were determined using Hitachi 737
Automatic Analyzer (Naka Works, Hitachi Ltd., Tokyo,
Japan). CSF and serum samples were kept at -800C if not
analyzed immediately. 
Concentrations of dopamine (DA), homovanillic acid
(HVA), 3,4-dihydoxyphenylacetic acid (DOPAC),
noradrenaline (NA), 3-methoxy-4-hydroxyphenylglycol
(MHPG), 5-hydroxytryptamine (5-HT) , and 5-
hydroxyindoleacetic acid (5-HIAA) were measured using
previously described methods.18 Measurements were also
made in serum, but since no differences was found these
were not considered further. Group analysis was done
using ANOVA and comparisons were made via t-test. A p-
value of <0.05 was considered significant. 
RESULTS
Baseline data on both PD groups along with healthy
controls are shown in Table 1.
In figure 1, we present CSF levels of dopamine and its
metabolites in PD patients and healthy controls. Both
Dopamine (DA) and its metabolite homovanillic acid (HVA)
decreased significantly in both On and Off PD patients,
while the level of 3,4-dihydroxyphenyl acetic acid (DOPAC)
remained unchanged. Figure 2 shows CSF levels of
noradrenaline (NA) and its metabolites 3-methoxy-4-
hydroxy phenyl glycol (MHPG) in PD patients and healthy
controls. Both NA and MHPG increased significantly in PD
patients. Figure 3 shows the correlation between NA and
NPY in CSF of PD patients and healthy controls. Figure 4
shows the correlation between dopamine and CCK
octapeptide in CSF of PD patients and healthy controls.
Figure 5 shows the correlation between NA and CCK
tetrapeptide in CSF of PD patients and healthy controls.
Figure 6 shows the correlat ion between 5-HT and
substance P in CSF of PD patients and healthy controls.
DISCUSSION
Parkinson's disease is an inexorably progressive disorder
that worsens over time. The rate of nigral cell death is not
exactly known, but neuro-imaging techniques estimate cell
death occurs at a rate of approximately 10% per year.19
PD symptoms are considered to be a consequence of an
imbalance between stimulatory and inhibitory impulses in
the extrapyramidal system, and that is mainly due to DA
transmission in the nigrostriatal pathway. 
Studies suggest that PD can develop in populations
exposed to pesticide, herebicide, well water and rural
living, and that the disease is not dependent on cigarette
smoking and caffeine consumption.20 The diagnosis of PD
generally relies on clinical observation of the combination
of four cardinal motor signs, namely tremor, rigidity,
bradykinesia and ba lance impai rment or postua l
i n s t a b i l i t y .2 1 These symptoms, especially the first three,
are typica ll y improved by dopamine rep lacement
therapies, and a positive response to L-dopa is mandatory
for the diagnosis of idiopathic PD. Long-term use of
carbidopa-levodopa can cause some potentially disabling
complications, including dyskinesias (involuntary muscle
movements or jerky motions), blepharospasm (involuntary
contraction of eyelid muscle), motor fluctuations, and
h a l l u c i n a t i o n s .2 2 Motor f luctuations involve random
conversion from a mobile state to an immobile state and
vice versa, also known as the “on-off” phenomenon.2 3
They are associated with fluctuating responses to L-dopa.
Patients respond to the drug during the “on” state and are
unresponsive during the “off” state.
Most PD patients treated with L-dopa develop fluctuations
in motor performance. After 3-5 years of treatment one-
third, after 5-7 years about half, and after 10-12 years,
nearly all patients suffer from motor fluctuations. Our
results suggest that neurotransmitter modulations,
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Table 1: Clinical data on the healthy controls and PD Patients in both On and Off groups
Patients N Females Age (years) CSF-Albumin CSF-IgG IgG-index
Controls 18 7 53 ± 7 218 ± 17 34 ± 4 0.44 ± 0.01
PD (On) 18 8 72 ± 12 332 ± 42** 51 ± 7** 0.43 ± 0.01
PD (On) 18 9 74 ± 14 313 ± 37* 44 ± 6* 0.42 ± 0.01
*p< 0.05, ** p< 0.01
Fig. 1: CSF levels of dopamine (DA) and its metabolites, HVA and
DOPAC in Parkinson patients (On and Off status) and healthy
subjects
Fig. 2: CSF levels of norepinephrine (NA) and its metabolite,
HMPG  in  Parkinson patients (On and Off status) and healthy
subjects
possibly in tandem with neuropeptide effects, may be the
mechanistic explanation underlying motor fluctuations in
PD.
An unbalanced overproduction of reactive oxygen species
(ROS) may give rise to oxidative stress which can induce
neuronal damage, ultimately leading to neuronal death by
apoptosis or necrosis. The clinical evidence demonstrating
that antioxidant compounds can act as protective drugs in
neurodegenerative disease is, however, relatively scarce.
The major challenges for drug development are the slow
kinetics of disease progression, the unsolved mechanistic
questions concerning the final causalities of cell death,
the necessity to attain an effective permeation of the
blood-brain barrier, and the need to reduce the high
concentrations currently required for protective effects in
cellular and animal model systems. 
The main metabolites of DA are HVA and DOPAC, and of
NA, 3-methoxy-4-hydroxyphenylglycol (MHPG). In PD
patients, the CSF NA and its metabolite, MHPG are
increased in both on and off groups while DA and its
metabolites DOPAC and HVA are significantly decreased in
both groups. Figures 1 and 2 show CSF levels of DA, NA,
and their metabolities in on and off PD patients, and are
compared with healthy controls. A single dose of L-dopa
gives a consistent response to motor activity in on
situation whereas when the disease progresses within a
few years, the response duration gets shorter, which is
when DA and its metabolites are further decreased in the
off situation (narrowed therapeutic window).
Apart from catecholamines, the estimation of serotonin
(5-HT) is related to depression, and it plays a very
important role in the CNS. We have already reported that
levels of tryptophan, 5-HT and 5-HIIA are significantly
decreased in both groups as both these groups are known
to be depressed and inactive.2 6 Apart from small
neurotransmitters such as catecholamines and amino
acids, recent research has also pointed to the role of
peptides in CNS.24-26
One of the major reasons for analyzing CSF peptides of
plasma and serum is that neuropeptides do not readily
cross the blood-brain barrier.1 0 Changes in the CSF
peptide concentration might be attributed to certain
symptoms and can even be interpreted as characteristic
features of certain pathological conditions. Neuropeptide
Y, cholecystokinin and substance P are some of the
important peptides that are believed to play vital biological
roles in various degenerative disorders.
Among the neuropeptides, NPY plays an important role in
anxiety, depression and eating disorders. The coexistence
of  NPY with other  neurotransmitters  and i ts wide
distribution in several brain areas predicts the high
importance of NPY as a neuromodulator. Thus, the effect
of NPY on the release of several neurotransmitters such
as glutamate,  gamma-aminobutyr ic  ac id (GABA),
norepinephrine (NE), dopamine, somastotatin (SOM),
serotonin (5-HT), nitric oxide (NO), growth hormone (GH),
and corticot ropin releasing factor (CRF) has been
examined.27 There is also evidence of its coexistence with
NA.28
Changes in NPY levels have been observed in different
pathological conditions such as brain ischemia and
neurodegenerative diseases (Huntington's, Alzheimer's
disease). Taken together, these studies suggest that NPY
and NPY receptors may represent pharmacological targets
in different patho-physiological conditions in the CNS.
Depression is a multi-factorial process; therefore, it is of
interest to study the coexistence of NPY with NA, 5-HT
and DA systems relevant to depression since various
neurological patients such as those with multiple sclerosis
and PD show signs of depression commonly.29
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Fig. 3: Correlation between norepinephrine (NA) and NPY in CSF
of Parkinson patients (On and Off status) and healthy subjects
Fig. 4: Correlation between dopamine and CCK-8s in CSF of
Parkinson patients (On and Off status) and healthy subjects
Low levels of NPY in CSF have been reported in depressed
patients, particularly in anxiety. However, all our PD
patients showed increased CSF level of  NPY. The
correlation between the levels of NPY shows a linear
relationship for PD patients which is similar to healthy
controls.
Besides NPY, CCK p lays a role in physiologica l,
neurological and psychiatric processes. A major role is gut
motility, pancreatic secretion and gall bladder contraction.
In addition, CCK has effects on locomotor activity,30 and
various reward behaviors includ ing cocaine and
amphetamine self-administration and food-related reward.
Furthermore, CCK plays a role in schizophrenia, anxiety
and Parkinson's disease3 1 and these findings have
confirmed a neurotransmitter role of CCK. Our knowledge
of CCK was greatly enhanced by the recent cloning of
cDNAs of rat preprocholecystokinin and the CCK
receptor.32 CCK-8 is believed to be the most prevalent
form of CCK in the CNS. It appears that CCK-8s and
various analogs may modulate CNS dopamine
neurotransmission and have been studied as a potential
antipsychotic agent.33 Among the other CCK peptides, its
tetrapeptide (CCK-4) is anxiogenic in humans and
considerable amount of data supports its role in anxiety
with panicogenic properties with minimal gastrointestinal
e f f e c t s .3 4 Other functional roles for central CCK (octa
peptide, CCK-8s) are as a mediator of satiety responses
and as a regulator of sexual and maternal behavior and of
seizure activity. The level of CCK-8s showed decreased
tendency in PD patients. Figures 4 and 5 show a linear
relationship between CSF CCK-8s and DA (Fig. 4) and the
similar relationship is seen between CSF CCK-4 and NA in
all PD patients (Fig. 5).
Similar to NPY and CCK, Substance P (SP) is a naturally-
occurring tachykinin peptide isolated from brain tissues
and gastrointestinal tract. In the brain, substantia nigra
and basal ganglia contain relatively high amounts of
substance P. There is evidence suggesting that substance
P functions as a neurotransmitter. It has been implicated
in the patho-physiology of several neuropsychiatric
disorders. Substance P may also serve as a useful tool in
studying the ef fects of antidepressant drugs and
electroconvulsive therapy.3 5 However, the contribution of
substance P to the understanding of neuropsychiatric
disorders is far from clear. SP has received great attention
due to its interaction with classical transmitters, especially
with 5-HT, NA and DA.3 6 Very few studies have been
conducted to study levels of SP in CSF from the patients
with neurological disorders. Figure 6 shows that a liner
relationship is found between SP and 5-HT in CSF for
healthy subjects as well as in PD patients groups, and
irrespective of On or Off status, this relationship and its
linearity is intact. 
One possible mechanism may be the difference in the
frequency dependence of the various transmitter pools.
The release of classical transmitter with low molecular
weight is generally believed to depend on the frequency by
which action potentials invade the nerve terminal. Brodin
et a l3 7 have shown in 1984 that the re lease of
neuropeptide as calculated per pulse recurred at high
frequencies compared with what usually is needed to
evoke the release of classical small molecule transmitters. 
One may conclude that neurodegeneration in PD patients
involves some combination of free radical (oxidative)
s tress, cytostatic  Ca2+, mitochndrial  damage,
excitotoxicity, deficiency of vitamins B12, B6 and folate,
and role of transition metals especially iron and copper.
The eventual result is cell death.
Future therapy in PD is likely to include a 'cocktail' of
neuroprotective compounds to interfere with several
molecular pathways that lead to neuronal injury. In using
therapeutic strategies aimed towards retarding or arresting
neuronal death, close attention will need to be paid to
quality of life issues. One of the main problems during the
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Fig. 6: Correlation between serotonin (5-HT) and Substance P in
CSF of Parkinson patients (On and Off status) and healthy subjects.
Fig. 5: Correlation between norepinephrine (NA) and CCK-4 in CSF
of Parkinson patients (On and Off status) and healthy subjects
many years of research on PD has been inability to detect
the disease early. New methods for early detection and
monitoring of disease progression - for example with
positron emission tomography in combination with
biochemical, pathological or behavioral analysis - will aid
in clinical diagnosis as well as future pharmacological
treatment that can halt further neurodegeneration and
nerve cell death. 
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